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The XV. Banff conference for allograft pathology was held in conjunction with the 
annual meeting of the American Society for Histocompatibility and Immunogenetics 
in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, 
advances from the Banff working groups, and standardization of molecular diagnos-
tics. This report on kidney transplant pathology details clarifications and refinements 
to the criteria for chronic active (CA) T cell–mediated rejection (TCMR), borderline, 
and antibody-mediated rejection (ABMR). The main focus of kidney sessions was 
on how to address biopsies meeting criteria for CA TCMR plus borderline or acute 
TCMR. Recent studies on the clinical impact of borderline infiltrates were also pre-
sented to clarify whether the threshold for interstitial inflammation in diagnosis of 
borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing micro-
vascular inflammation in the absence of C4d staining or detectable donor-specific 
antibodies; the potential value of molecular diagnostics in such cases and recommen-
dations for use of the latter in the setting of solid organ transplantation are presented 
in the accompanying meeting report. Finally, several speakers discussed the capabili-
ties of artificial intelligence and the potential for use of machine learning algorithms 
in diagnosis and personalized therapeutics in solid organ transplantation.
K E Y W O R D S
classification systems: Banff classification, clinical decision-making, clinical research/practice, 
kidney (allograft) function/dysfunction, kidney transplantation/nephrology, molecular biology: 
mRNA/mRNA expression, pathology/histopathology, rejection, translational research/science
1  | INTRODUC TION
The XV. Banff Conference for Allograft Pathology was held 
September 23-27, 2019, in Pittsburgh, PA (USA), in conjunction with 
the Annual Meeting of the American Society for Histocompatibility 
and Immunogenetics (ASHI). A total of 1253 delegates from 31 
countries attended the conference, including pathologists, immunol-
ogists, physicians, surgeons, and immunogeneticists as well as rep-
resentatives from industry. The focus of kidney sessions at the 2019 
conference was to clarify diagnostic criteria for antibody-mediated 
rejection (ABMR) and chronic active (CA) T cell–mediated rejection 
(TCMR) to harmonize the pathologic diagnosis and consequent 
therapeutic strategies. In addition, consensus of the diagnosis of 
borderline (suspicious) for acute TCMR was reached. The current lit-
erature on biomarkers and molecular transplant diagnostics was also 
reviewed, and recommendations of the Banff Molecular Diagnostics 
Working Group regarding clinical validation and adoption of the 
latter into the Banff classification will be presented in a separate 
meeting report. Continuing a theme from the Banff 2015 meeting,1 
results of studies using artificial intelligence (AI) and integrative epi-
demiological approaches were presented. Their applicability in pre-
diction, prognostication, and clinical trials could change standards of 
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care for transplant recipients.2 The conference was preceded by a 
premeeting on “Regenerative Medicine and Digital Pathology” and 
a joint session between the ASHI and Banff key opinion leaders, 
which presented insights into future tissue and organ engineering 
and new technologies in solid organ transplantation. Precise detec-
tion and characterization of anti-HLA or non-HLA donor-specific an-
tibodies (DSAs) was also revisited. This report summarizes the main 
outcomes of the Banff 2019 kidney sessions and their impact on the 
Banff classification.
2  | UPDATES FROM THE BANFF WORKING 
GROUPS
The current active and new Banff working groups (BWGs) and their 
aims, leaders, and progress are listed in Table 1. One new BWG has 
been formed, the Digital Pathology BWG. The aim of this working 
group is to define standards for digital pathology in the context of 
Banff lesion scores in order to standardize diagnostic scoring and 
reduce inter-observer variability. In addition, the peritubular capil-
laritis (ptc) BWG has been reactivated. Recent studies have shown 
diagnostic and prognostic relevance of reporting the extent of cap-
illaritis (diffuse vs focal) in addition to the Banff ptc score, in dif-
ferent clinical scenarios including ABMR, mixed ABMR/TCMR, and 
low-grade microvascular inflammation (MVI).3,4 The aim of the BWG 
is to validate these findings in a multicenter study, and to evaluate 
optimal diagnostic thresholds.
At its meeting during Banff 2019, the electron microscopy (EM) 
BWG expanded on its previous recommendations1,5 and agreed to 
guidelines for tissue sampling and performing EM analysis for as-
sessment of cg1a and peritubular capillary basement membrane 
multilayering (PTCML). These are summarized in Table 2. The group 
also recommended the use of specific terminology aligned where 
possible with ongoing work of the Renal Pathology Society work-
ing group developing consensus definitions for individual glomeru-
lar lesions by light microscopy and EM. As specified in Table 3, this 
includes the following, representing individual components of very 
early lesions of transplant glomerulopathy (cg1a): endothelial cell en-
largement, subendothelial electron-lucent widening, and subendothelial 
neo-densa glomerular basement membrane. Reporting of other endo-
thelial and basement membrane features in glomeruli and peritubu-
lar capillaries (PTCs) is left to the discretion of the pathologist as 
there are few data to support their use at present. Based on consen-
sus opinion within the EM BWG, abbreviation for peritubular capil-
lary basement membrane multilayering is recommended as PTCML.
At the 2019 conference, final data from the BWG on the clas-
sification of polyomavirus nephropathy (PVN) were presented. This 
BWG studied 192 patients with definitive PVN and identified two 
histologic markers predictive for graft function and graft survival: the 
Banff interstitial fibrosis (ci) score and a new score termed “the intra-
renal polyomavirus load level” or pvl, the latter based on the fraction 
of tubules with evidence of PV replication by light microscopy OR 
immunohistochemical staining of epithelial cell nuclei for SV40 large 
T antigen (pvl1 ≤ 1%, pvl2 > 1%, and <10%, pvl3 ≥ 10%). The pvl and 
ci scores were used to define 3 PVN classes (Tables 4 and 5).6
3  | CL ARIFIC ATION AND UPDATES 
TO THE BANFF 2017 CL A SSIFIC ATION 
RE VISIONS
The Banff 2019 kidney sessions focused on reviewing the impact of 
the changes to the diagnostic criteria for both TCMR and ABMR that 
were made at the 2017 Banff conference.5 For TCMR, this involved 
mainly the implementation of CA TCMR: The extent to which this cat-
egory is being used at different centers around the world, potential 
confusion regarding the wording of diagnoses within this category, 
how frequently patients with CA TCMR were being treated, and the 
efficacy of those treatments. The threshold for the interstitial inflam-
mation score (i) in the diagnosis of borderline for acute TCMR, which 
has not been applied uniformly by different pathologists7 and been 
the subject of recent investigation8,9 was also discussed. For ABMR, 
discussions centered around potential simplification of the diagnos-
tic criteria, including clarifying the description of activity and chro-
nicity components within the category of CA ABMR—making the 
resultant report more intelligible and useful to treating clinicians.10 
Standardized reporting for TCMR and ABMR diagnoses were dis-
cussed, including the inclusion of individual Banff acute and chronic 
scores (i, t, g, cg, and so on) used in determining the subtype, activ-
ity. and chronicity and explanations of these scores.1,7 The clinical 
implications of MVI in the absence of (DSAs with and without C4d 
deposition were also presented). Final consensus recommendations 
were aided by questionnaires distributed to pathologists, nephrolo-
gists, and transplant surgeons attending the 2 kidney-specific ses-
sions during and immediately after the meeting (Table 6).
3.1 | Chronic active TCMR criteria clarifications
To assess whether transplant centers worldwide were applying 
the 2017 Banff classification and diagnosing CA TCMR, we en-
listed the assistance of The Transplantation Society (TTS) and the 
CyberNephrology online forum (Dr Kim Solez) in circulating a sur-
vey that was answered by 128 TTS members, including clinicians 
and pathologists, from six different continents before the meet-
ing (Figure 1). Notably, pathologists at ~90% of surveyed centers 
diagnosed CA TCMR, and at >80% of these centers at least some 
patients with this diagnosis were treated with steroids or other im-
munosuppressive agents. However, those clinicians that do not rou-
tinely treat patients with CA TCMR (52/81, 64%) indicated a need 
for more definitive data on the efficacy of CA TCMR treatment, and 
a minority (22/81, 27%) felt that the risk of treatment outweighs the 
benefits. Two points that should be emphasized regarding CA TCMR 
are that inflammation in areas of the cortex with interstitial fibrosis 
and tubular atrophy (i-IFTA), while an essential component of CA 
TCMR, are not sufficient to make this diagnosis, which also requires 
     |  2321LOUPY et aL.
TA B L E  1   Updates of Banff working groups
Working group Leaders Issues to address Group progress/future plans
TCMR V. Nickeleit
P. Randhawa
Integration of i-IFTA into classification; 
reevaluate thresholds for i and t and 
possible addition of other findings (eg, 
edema) to TCMR diagnostic criteria
A multicenter clinicopathologic study aimed at addressing the 
listed issues is in progress. To date biopsies and accompanying 
clinical data from 154 patients with “pure” (no ABMR) acute 
TCMR/borderline, 18 with chronic active TCMR, 55 with 
no rejection. and 31 patients with stable graft function (not 
biopsied) have been accrued into the study cohort. Data 
analysis and slide review have commenced, but more cases, 
especially cases of chronic active TCMR and control cases 
with complete clinical data for statistical analysis of TCMR/
borderline thresholds, are required. These cases need to 
have documented absence of DSA and sufficient follow-up in 








Define criteria for highly sensitized patients 
(HS), determine consensus for what 
personnel and facilities are needed for 
centers to perform transplantation in HS 
recipients, standardize the definitions 
related to management of sensitized 
transplant recipients. Evaluate current 
practices of centers performing renal 
transplants in sensitized recipients. 
Evaluate how clinicians interpret and apply 
Banff nomenclature, and recommend 
changes to wording of classification to 
optimize the use of Banff data in clinical 
care of HS patients.
Survey regarding clinical practice related to highly sensitized 
(HS) patients indicates that clinicians often fail to recognize 
chronic elements of ABMR (eg, cg > 0) and are more likely to 
consider a diagnosis of chronic active ABMR if C4d is negative, 
even if there is no TG, PTCML, or IFTA. The term “acute” is 
confusing in ABMR, and consequently it was removed from 
the Banff ABMR classification in 2017.3 Further improved 
communication between pathologists and clinicians regarding 
reporting of biopsy findings in HS. Follow-up preliminary 
survey results indicate that pathologists and clinicians 
have similar concerns about biopsy reporting of antibody-
mediated injury: Banff classification is complex, changes 
frequently, and does not reflect the entire ABMR disease 
spectrum. Comprehensive literature review is in progress to 
outline patient risk spectrum with respect to antibody and to 





Develop consensus discovery gene panel, 
which becomes available to the whole 
transplant community as standardized 
commercially available reagents. Design 
and conduct collaborative studies to 
validate clinical utility of molecular 
diagnostics in transplant biopsies.
Launch of a consensus based, commercially available 
(NanoString Inc), standardized Banff Human Organ Transplant 
(B-HOT) discovery gene panel, which can reproducibly be 
applied to FFPE samples across organs and in multicenter 
studies. Development of an open source data sharing platform 
to exchange results from studies using the B-HOT panel and to 
allow multicenter and multiorgan validation of clinical utility of 




S. Bagnasco Compare kidney transplants from HIV+ 
and HIV-negative donors to HIV+ 
recipients with regard to graft function 
and graft survival, · incidence, type and 
pathologic features of allograft lesions 
including rejection, recurrent and de novo 
HIV-related/-unrelated renal disease; 
injury associated with antiretroviral and 
immunosuppressive treatment.
Based on preliminary data from the pilot phase of the US 
HOPE prospective multicenter trial for HIV+ to HIV+ kidney 
transplantation, TCMR is predominant, rejection appears to be 
unrelated to donor HIV status and may possibly be related to 
the type of immunosuppression. Additional data will become 
available with ongoing trial enrollment in upcoming years. 
The results of protocol/indication biopsies (archived as digital 
images), combined with comprehensive clinical information will 





Recommendations for the sampling and 
processing of tissue for EM and reporting 
of EM findings in transplant biopsies. 
Harmonize terminology with a list of 
definitions for cg1a and PTCML. Reduce 
inter-observer variability in the use of 
uniform guidelines for the evaluation 
of TG and PTCML Multicenter study 
of the natural history, associations and 
the predictive value of glomerular and 
peritubular capillary ultrastructural 
features (endothelium; basement 
membrane; electron dense deposits).
Consensus document produced at Banff 2019 meeting. 
Results of initial survey of interobserver variability were poor 
(presented at Banff 2017); a new comprehensive teaching 
module will focus on the most problematic lesions gleaned 
from the 2017 survey; Goal is to improve the uniform use of 
currently published criteria and the inter-observer variability. 
Research proposal presented at Banff 2019: pilot test case 
data collection in 2020; final study design to be agreed upon 
before initiation of the full study in 2020-21. Goal is the 
multicenter validation of ultrastructural features through 
correlation with outcomes.
(Continues)
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Establish uniform diagnostic criteria for 
TMA. Determine the frequency with 
which TMA occurs in renal allograft biopsy 
specimens. Determine if there are specific 
features of TMA in renal allografts that 
help resolve the differential diagnosis of 
the TMA when the cause is not readily 
apparent from clinical history, DSA, C4d, 
etc
Using Delphi methodology, two phases were designed: Phase 
I (with pathologists) and Phase II (with clinicians). Phase I (6/9 
rounds completed) involving 23 centers; 1. We collected 37 
transplant biopsies, and after 6 Delphi rounds, narrowed down 
331 criteria to 61; 2. We classified the criteria into 4 classes 
(Pathology, Clinical, Laboratory and Differential Diagnosis) and 
12 categories reflecting positive and negative criteria for LM, 
IF, EM, clinical, laboratory and genetic criteria; 3. Participants 
validated the 37 cases in 2 validation rounds. Results showed 
that 75% of the participants reached consensus in over 75% 
of cases, using the 61 criteria. 4. We identified the reasons 
for over- and under-diagnosis of TMA. Results of rounds 7, 8 
and 9 are pending. Phase II: Recruitment of participants for 
the clinical Delphi starting January 2020. Future efforts will 
focus on completing the 3 remaining Delphi rounds (Phase 
I), soliciting nephrologists’ input (Phase II), combining Phase I 
and II results, dissecting diagnostic issues that emerged during 
Phase I, such as ABMR mimicking TMA and completing the 
molecular studies to generate the final consensus guidelines. 
The WG also plans to collaborate with groups that are working 







Establish pathologic guidelines for early 
recurrence of glomerular diseases, 
including FSGS, IgA nephropathy, 
membranous nephropathy, MPGN/
C3GN. What are frequencies, clinical 
manifestations, and pathologic 
characteristics of recurrent/de novo 
glomerular diseases, and can any of these 
predict recurrence and/or graft outcomes? 
Understand the pathologic changes of 
recurrent glomerular diseases occurring 
concurrently with rejection and other 
transplant-associated lesions.
Biopsy specimens and clinical data are now being collected 
from 10 international centers. Preliminary results confirm 
IgA nephropathy and FSGS as the most prevalent recurrent 
diseases. Combine all data to create a posttransplant GN 
registry. Future directions:
• Correlate GN findings with Banff classification
• Correlate pathology with biomarkers, DSA, etc
• Determine if outcomes of posttransplant GN can be 
improved with early detection, prevention and therapy. Are 
there clinical and/or pathologic features of the native disease 
that predict likelihood of recurrence? Are there clinical and/
or pathologic features of the recurrent disease in the allograft 
that predict graft loss?
Which pathologic analyses are needed for optimal and early 
diagnosis of recurrent disease? Is the apparent association 
of recurrent glomerular disease with acute rejection 
related to biopsy bias (ie incidental discovery of recurrent 






Define valid surrogate endpoints and 
invasive or noninvasive biomarkers for 
clinical trials and how histology and lesions 
related to tissue injury or scarring have to 
be integrated in such systems. Insure Banff 
active involvement and interactions with 
agencies such as FDA/ EMA and societies 
(AST, ESOT, TTS).
New WG in progress




Elaboration of diagnostic algorithms 
for the Banff Diagnostic Classes 1-6. 
Determination of the needs of the 
transplant community for dissemination of 
Banff content. Predominantly web-based 
dissemination of Banff content.
Collation of all Banff content for kidney allograft pathology 
up to and including Banff 2017 (Transplantation 2018; 
102:1795-1814). Future plans include survey of the transplant 
community regarding dissemination needs, podcast based on 
the 2018 review article in collaboration with TTS, development 
and implementation of web-based tools and dissemination 
of relevant Banff content including the content of this 2019 
update.
TA B L E  1   (Continued)
(Continues)
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(1) at least a moderate degree of total cortical inflammation and (2) 
moderate tubulitis involving cortical tubules other than severely 
atrophic tubules (Table 4). i-IFTA itself is not a specific lesion and is 
seen in the context of tissue injury due to many causes other than 
TCMR, including BK virus nephropathy and ABMR.11 According to 
Banff 2017,5 the tubulitis allowed for the diagnosis of CA TCMR may 
be within or outside of scarred areas. However, for clarity and future 
investigation we suggest that tubulitis be independently scored (pro-
viding that severely atrophic tubules are not scored) both in areas of 
preserved cortex (Banff t score) and within (Banff t-IFTA score) areas 
of cortical IFTA, as defined in Table 5. This may enable investiga-
tors and clinicians to determine the impact on treatment response 
and graft survival of these different forms of tubulitis. An important 
concern expressed by some clinicians and pathologists is that the 
Banff 2017 diagnosis of CA TCMR does not discriminate between 
cases where all or nearly all inflammation is limited to i-IFTA vs those 
instances where coexistent i-IFTA and inflammation within non-
scarred areas meets criteria for additional borderline acute TCMR 
or acute TCMR grade IA or IB diagnoses. Questionnaire responses 
from meeting attendees clearly replied that reporting of “mixed” 
CA TCMR with grade IA or IB acute TCMR could be improved by 
indicating separately when biopsies simultaneously met criteria for 
borderline for acute TCMR or acute TCMR grade IA or IB (Table 6). 
Likewise, participants agreed that when intimal arteritis was present 
in addition to CA TCMR, this should also be specifically reported 
as a separate reported diagnosis. These suggestions pertain only to 
CA TCMR reporting and the actual histologic criteria for this diag-
nosis remain unchanged (Tables 4 and 5). Nankivell et al12 reported 
that both development of i-IFTA and clearance of inflammation from 
scarred areas were dependent of the efficacy of immunosuppressive 
therapy. These data support the 2017 Banff criteria for CA TCMR, 
but also favor indicating the level of active inflammation in non-
scarred cortex.
3.2 | Borderline (suspicious) for acute TCMR criteria 
clarifications
The Banff ’97 criteria for diagnosis of borderline for acute 
TCMR required inflammation in at least 10% of nonscarred cor-
tex (Banff i1) in addition to tubulitis.13 However, subsequent 
iterations of the Banff classification (1) accepted tubulitis with 
minimal inflammation (isolated t; i0 t > 0) as sufficient for a di-
agnosis of borderline, and a recent survey showed variability 
among pathologists with regard to which threshold was used for 
this diagnosis.7 More recently, longitudinal studies of Nankivell 
et al9 showed no effect of isolated t lesions on graft outcomes, 
concluding that the original Banff ’97 threshold for borderline 
lesions should be applied, and 82% (57/69) of pathologists and 
clinicians (nephrologists and transplant surgeons) responding 
to the questionnaire distributed at the 2019 Banff conference 
agreed (Table 6). Consensus was therefore achieved that the di-
agnostic threshold for borderline for acute TCMR should read 
as follows: “interstitial inflammation involving 10%-25% of non-
sclerotic cortex (Banff i1) with at least mild tubulitis (t > 0).” The 
minimum lesion for a borderline diagnosis is thus i1t1. As with 
previous versions of the Banff classification,1,13 lesions charac-
terized by mild tubulitis (Banff t1) with inflammation involving 
>25% of nonsclerotic cortex (Banff i2/3) and no intimal arteritis 
are also included in the borderline category (Table 4). However, 
Working group Leaders Issues to address Group progress/future plans
Digital pathology K. Solez
A. B. Farris
Digital automation of pathology practice: 
computing, artificial intelligence, 
nanotechnology, machine learning, slide 
numerization.
Standardization of practices, classification for studies using 
integrative approaches, IFTA scoring, inflammation scoring, 
algorithms to fit to the classification and decrease inter-
observer variability. Archetypes to be validated across multiple 
institutions.







Evaluation whether a combined view of ptc 
score and ptc extent is superior compared 
to the currently applied standard of care 
(only ptc score) in distinguishing the role 
of ptc in the following diagnostic settings: 
active and chronic active ABMR, acute 
and chronic active TCMR/borderline, 
low-grade MVI and mixed ABMR/TCMR. 
Test the reproducibility and prognostic 
significance of the combined of ptc score 
and extent. Gene expression analysis 
of peritubular capillaritis in different 
diagnostic settings. Comparison of cortical 
ptc vs medullary ptc (vasa recta).
Multicenter validation cohort study is under preparation, for 
collection, centralization, assessment and circulation of a 
subset of cases from different diagnostic groups for inter-
observer agreement is planned for 2020-2021. Prognostic 
significance of a peritubular capillaritis grade incorporating 
both ptc score and extent will be investigated
Abbreviation: FFPE, formalin-fixed, paraffin-embedded.
TA B L E  1   (Continued)
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biopsies with tubulitis (t > 0) but without inflammation in at least 
10% of nonsclerotic cortex (i0) are no longer included in this cat-
egory, and neither are cases with inflammation in the absence of 
tubulitis (i > 0, t0). These are simply reported in the microscopic 
description of the biopsy.
3.3 | ABMR criteria clarifications
Since the introduction of ABMR into the Banff classification in 
2003,14 the criteria for diagnosis of ABMR have become more 
complex, with major modifications in 201315 and 2017,5 which 
have improved diagnostic sensitivity and predictive value for graft 
outcomes.16 A major residual issue within the classification is that 
it still subclassifies ABMR into active or chronic active and chronic 
inactive (ie, transplant glomerulopathy without MVI and with cur-
rent or historic DSA; Table 4) subtypes as opposed to representing 
the diverse morphologic and molecular lesions at different post-
transplant time points in antibody-mediated tissue injury.17,18 In 
particular, the category of CA ABMR encompasses lesions with 
severe activity and mild chronicity (eg, g3 ptc3 cg1 ci0 ct0 C4d3), 
those with mild activity and severe chronicity (eg, g1 ptc1 cg3 ci3 
ct3 C4d0), and intermediate cases. Thus a simple diagnosis of CA 
ABMR gives treating clinicians limited information for appropri-
ate treatment options. Although the addition of individual Banff 
lesion scores to the diagnostic line of the report is interpretable 
by experienced clinicians, it may confuse some clinicians who are 
unfamiliar with subtleties of the Banff system. This concern was 
highlighted by the recent work from the BWG on highly sensitized 
patients who found that the classification was interpreted in a 
highly variable way with implications for resultant therapeutic de-
cision making.10,19 Potential improvements in the wording of the 
pathologic diagnoses in standard reports were discussed, which 
remained within the context of Banff 2017 to optimally convey 
the activity and chronicity levels of CA ABMR cases. For example, 
in lupus nephritis,20 the previous designations of active (A), active 
and chronic (A/C), and chronic (C) were replaced with a revised 
TA B L E  2   Banff recommendations for electron microscopy in 
renal transplant biopsies
Recommendations for taking of a sample for EM
Take a sample in all cases if possible, fixed and embedded as a resin 
block. At a minimum, this should be done if there is any suspicion 
of glomerular disease. While EM can be performed on samples 
recovered from paraffin blocks or frozen tissue to examine for 
electron dense deposits and to some extent the degree of foot 
process effacement, this is not recommended for assessment of 
glomerular basement membrane (GBM) thickness, cg1a or PTCML. 
In all cases, light microscopic (LM) examination of semi-thin stained 
sections should be performed.
Recommendations for performing ultrastructural analysis
Recommended in cases with: (a) Clinical, light microscopic and/or 
immunohistochemical suspicion of glomerular disease or of other 
diseases where EM may assist in diagnosis; (b) Patients at risk for 
antibody-mediated rejection (ABMR): patients who are sensitized, 
have documented DSA at any time posttransplant, and/or who 
have had a prior biopsy showing features of ABMR (C4d staining, 
glomerulitis and/or peritubular capillaritis).
EM can also be useful: (a) To detect early recurrence in patients with 
biopsy-proven glomerular disease as the cause of native kidney failure; 
(b) In for-cause biopsies ≥3 mo posttransplant, and in all biopsies 
≥6 mo posttransplant, to determine if early changes of transplant 
glomerulopathy (cg1a) are present, prompting testing for DSA.
In all cases, undertake an assessment for glomerular disease as in a 
native renal biopsy.
If performing EM in the setting of possible ABMR, assess for cg1a 
and PTCML as recommended below.
Recommendations for preparing the block for ultrastructural 
examination
Select an area in the resin block(s) of viable (non-necrotic) cortex, 
preferentially with minimal tubular atrophy/interstitial fibrosis. 
Aim to include ≥2 full glomeruli (at least 1). Do not taper the block 
to a “cone” or “pyramid” by removing cortical tissue around the 
glomeruli and aim to have at least 10 peritubular capillaries (PTCs) 
for examination.
Guidelines for ultrastructural assessment and reporting of cg1a
Exclude globally or partly sclerosed glomeruli, and severely ischemic 
glomeruli.
Examine 1 complete glomerulus as a minimum; where possible 
examine 2 or more.
Examine the capillary loops at high magnification (≥5000x).
cg1a is defined as: (a) No GBM double contours on LM; (b) 
≥3 capillary loops (in a single glomerulus) each showing: 
subendothelial neo-densa glomerular basement membrane 
(circumferential or not, single or multiple layers) AND endothelial 
cell enlargement and/or subendothelial electron-lucent widening.
The report should state how many glomeruli were examined, and 
how many loops show cg1a.
Guidelines for ultrastructural assessment and reporting of PTCML
Assess for PTCML in the cortical peritubular capillaries between the 
glomeruli.
Exclude scarred cortex and necrotic or hemorrhagic areas.
Examine at least 10 PTC at high magnification (≥ 5000×).
Count layers of basement membrane (BM) in the 3 worst affected 
PTCs, for each counting in the PTC segment with the most layers 
(worst affected area along the circumference).
The report should state the number of PTC examined; the number 
of BM layers in the most affected PTC; and whether the Banff 
2013 threshold for chronic ABMR (ptcml1; 1 PTC with ≥7 layers +2 
PTC with ≥5 layers) is met.
TA B L E  3   Definitions of the individual components of early 
lesions of transplant glomerulopathy
• Endothelial cell enlargement is defined as glomerular endothelial 
enlargement with associated increase in cytoplasm, decrease in 
the capillary luminal area and loss of fenestrations. This should 
be used rather than less precise or incorrect terminology such 
“endothelial swelling”, “reactive endothelial changes”, “endothelial 
activation”, “endothelial injury” or “endothelial cell degeneration”.
• Subendothelial electron-lucent widening is defined as expansion 
of space between the glomerular endothelium and lamina densa 
of the glomerular basement membrane (GBM) by electron-lucent 
material. This should be used instead of “lamina rara interna 
expansion” or “subendothelial rarefaction”.
• Subendothelial neo-densa glomerular basement membrane is 
defined as circumferential or discontinuous, single or multiple 
basement membrane layer(s) clearly distinct from the original 
GBM.
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TA B L E  4   Updates of 2019 Banff classification for ABMR, 
borderline changes, TCMR, and polyomavirus nephropathy. All 
updates in boldface typea
Category 1: Normal biopsy or nonspecific changes
Category 2: Antibody-mediated changes
Active ABMR; all 3 criteria must be met for diagnosis
1. Histologic evidence of acute tissue injury, including 1 or more of 
the following:
• Microvascular inflammation (g > 0 and/or ptc > 0), in the absence 
of recurrent or de novo glomerulonephritis, although in the 
presence of acute TCMR, borderline infiltrate, or infection, 
ptc ≥ 1 alone is not sufficient and g must be ≥ 1
• Intimal or transmural arteritis (v > 0)b 
• Acute thrombotic microangiopathy, in the absence of any other 
cause
• Acute tubular injury, in the absence of any other apparent cause
2. Evidence of current/recent antibody interaction with vascular 
endothelium, including 1 or more of the following:
• Linear C4d staining in peritubular capillaries or medullary vasa 
recta (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by IHC 
on paraffin sections)
• At least moderate microvascular inflammation ([g + ptc] ≥2) in the 
absence of recurrent or de novo glomerulonephritis, although in 
the presence of acute TCMR, borderline infiltrate, or infection, 
ptc ≥ 2 alone is not sufficient and g must be ≥1
• Increased expression of gene transcripts/classifiers in the biopsy 
tissue strongly associated with ABMR, if thoroughly validated
3. Serologic evidence of circulating donor-specific antibodies (DSA 
to HLA or other antigens). C4d staining or expression of validated 
transcripts/classifiers as noted above in criterion 2 may substitute 
for DSA; however thorough DSA testing, including testing for 
non-HLA antibodies if HLA antibody testing is negative, is strongly 
advised whenever criteria 1 and 2 are met
Chronic active ABMR; all 3 criteria must be met for diagnosis
1. Morphologic evidence of chronic tissue injury, including 1 or more 
of the following:
Transplant glomerulopathy (cg > 0) if no evidence of chronic TMA 
or chronic recurrent/de novo glomerulonephritis; includes changes 
evident by electron microscopy (EM) alone (cg1a)
Severe peritubular capillary basement membrane multilayering 
(ptcml1; requires EM)
Arterial intimal fibrosis of new onset, excluding other causes; 
leukocytes within the sclerotic intima favor chronic ABMR if there 
is no prior history of TCMR, but are not required
2. Identical to criterion 2 for active ABMR, above
3. Identical to criterion 3 for active ABMR, above, including strong 
recommendation for DSA testing whenever criteria 1 and 2 
are met. Biopsies meeting criterion 1 but not criterion 2 with 
current or prior evidence of DSA (posttransplant) may be stated 
as showing chronic ABMR, however remote DSA should not be 
considered for diagnosis of chronic active or active ABMR
Chronic (inactive) ABMR
1. cg > 0 and/or severe ptcml (ptcml1)
2. Absence of criterion 2 of current/recent antibody interaction with 
the endothelium
3. Prior documented diagnosis of active or chronic active ABMR 
and/or documented prior evidence of DSA
(Continues)
C4d staining without evidence of rejection; all 4 features must be 
present for diagnosisc 
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF 
on frozen sections, or C4d > 0 by IHC on paraffin sections)
2. Criterion 1 for active or chronic active ABMR not met
3. No molecular evidence for ABMR as in criterion 2 for active and 
chronic active ABMR
4. No acute or chronic active TCMR, or borderline changes
Category 3: Borderline (Suspicious) for acute TCMR
Foci of tubulitis (t1, t2, or t3) with mild interstitial inflammation (i1), 
or mild (t1) tubulitis with moderate-severe interstitial inflammation 
(i2 or i3)
No intimal or transmural arteritis (v = 0)
Category 4: TCMR
Acute TCMR
Grade IA: Interstitial inflammation involving >25% of non-sclerotic 
cortical parenchyma (i2 or i3) with moderate tubulitis (t2) involving 
1 or more tubules, not including tubules that are severely atrophicd 
Grade IB: Interstitial inflammation involving >25% of non-sclerotic 
cortical parenchyma (i2 or i3) with severe tubulitis (t3) involving 1 
or more tubules, not including tubules that are severely atrophicd 
Grade IIA: Mild to moderate intimal arteritis (v1), with or without 
interstitial inflammation and/or tubulitis
Grade IIB: Severe intimal arteritis (v2), with or without interstitial 
inflammation and/or tubulitis
Grade III: Transmural arteritis and/or arterial fibrinoid necrosis 
involving medial smooth muscle with accompanying mononuclear 
cell intimal arteritis (v3), with or without interstitial inflammation 
and/or tubulitis
Chronic active TCMRe 
Grade IA: Interstitial inflammation involving >25% of sclerotic 
cortical parenchyma (i-IFTA2 or i-IFTA3) AND > 25% of total 
cortical parenchyma (ti2 or ti3) with moderate tubulitis (t2 or 
t-IFTA2) involving 1 or more tubules, not including severely 
atrophic tubulesd ; other known causes of i-IFTA should be ruled 
out
Grade IB: Interstitial inflammation involving >25% of sclerotic 
cortical parenchyma (i-IFTA2 or i-IFTA3) AND > 25% of total 
cortical parenchyma (ti2 or ti3) with severe tubulitis (t3 or t-IFTA3) 
involving 1 or more tubules, not including severely atrophic 
tubulesd ; other known causes of i-IFTA should be ruled out
Grade II: Chronic allograft arteriopathy (arterial intimal fibrosis 
with mononuclear cell inflammation in fibrosis and formation of 
neointima). This may also be a manifestation of chronic active or 
chronic ABMR or mixed ABMR/TCMR
Category 5: polyomavirus nephropathyf 
PVN Class 1
pvl 1 and ci 0-1
PVN Class 2
pvl 1 and ci 2-3 OR
pvl 2 and ci 0-3 OR
pvl 3 and ci 0-1
PVN Class 3
pvl 3 and ci 2-3
TA B L E  4   (Continued)
(Continues)
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version of the old National Institutes of Health (NIH) activity and 
chronicity indices in a more granular fashion. However, the appli-
cability of this approach to transplantation remains to be validated. 
Questionnaire respondents were also asked to select the optimal 
wording of the current Banff 2017 ABMR diagnosis from several 
options detailing activity and chronicity information, and how to 
best incorporate relevant Banff lesion scores into the final report. 
The option preferred by 56% of respondents was to word the di-
agnosis line as follows: “(chronic) active ABMR with [mild, moder-
ate, severe] activity and [mild, moderate, severe] chronicity” and 
include the Banff lesion scores in the text of the diagnostic line for 
the biopsy report or in a table (eg, Tables 5 and 6). However, the 
definitions and optimal thresholds for mild, moderate, and severe 
still need to be validated in future studies, and as such, it remains 
at the discretion of individual pathologists whether to adopt such 
wording at this time or simply provide the Banff lesion scores. It 
should also be emphasized that these suggestions pertain only to 
the CA ABMR reporting language, and the actual histologic crite-
ria for diagnosis of CA ABMR, as specified in Banff 2017, remain 
unchanged.5
3.4 | Microvascular inflammation in the absence of 
detectable DSAs
At the Banff 2017 conference, updates to the ABMR classification 
were made to help with decision-making in cases where a biopsy 
showed at least moderate MVI ((g + ptc) >2) but no detectable anti-
bodies against the graft.5 However, there are considerable numbers 
of biopsies with (g + ptc) >2 in the absence of detectable anti-HLA 
DSAs or C4d, and with molecular ABMR testing not widely adopted 
at this point, the clinical implications of these findings remain unclear. 
Recent evidence has suggested that patients with MVI on biopsies 
performed early posttransplant in the absence of DSAs had signifi-
cantly better graft survival than those with anti-HLA DSAs (mainly 
low-level, preexisting DSAs), regardless of the presence or absence 
of PTC C4d staining on the biopsy.21 DSA+ patients were more fre-
quently retransplant recipients and had C4d+ biopsies. By contrast, 
studies of patients biopsied much later with more severe MVI and 
frequent transplant glomerulopathy (TG) showed no difference in 
graft survival in the presence or absence of anti-HLA DSAs, which 
in these studies were de novo DSAs.22,23 Thus, at this point, we are 
unable to draw significant conclusions regarding the significance 
of biopsies showing (g + ptc >2) in the absence of anti-HLA DSAs, 
other than to comment that the biological behavior of such changes 
may well differ depending on whether these are seen relatively early 
posttransplant at a time when many DSAs represent persistent or 
recurrent/memory DSAs vs those seen later when most DSAs de-
tected are de novo DSAs. In addition, the differential diagnosis of 
MVI with negative DSA and negative C4d should include T cell–me-
diated endothelial injury (ptc), membranoproliferative glomerulone-
phritis (g), and thrombotic microangiopathy (g). Furthermore, it has 
been shown recently in large populations that non-HLA antibodies 
could be independently associated with risk of allograft loss.24 These 
findings emphasize the importance of testing for clinically relevant 
non-HLA antibodies in patients with biopsies showing MVI.
It is also hoped that implementation of molecular diagnostics could 
help classifying these cases in a more pathogenesis-driven way, either 
employing the Molecular Microscope Diagnostic System (MMDx)25 or 
the NanoString platform that can be used with formalin-fixed, paraf-
fin-embedded tissue,26 providing greater insight into factors predictive 
of the biological behavior of MVI without detectable anti-HLA DSAs, 
as well as cases with C4d staining without MVI.27 Current recommen-
dations of the Banff Molecular Diagnostics Working Group in these 
and other circumstances are detailed in a separate meeting report. 
Presently, however, available data do not warrant making changes to 
the ABMR classification specifically relevant to these cases, beyond 
those made in Banff 2017.5
4  | ROLE OF ARTIFICIAL INTELLIGENCE , 
DATA INTEGR ATION, AND MACHINE 
LE ARNING IN THE BANFF CL A SSIFIC ATION
During the 2019 Banff meeting, many projects using artificial intelli-
gence (AI), machine learning (ML), as well as deep learning (DL) were 
presented, with a heavy focus on applying the Banff classification in 
an automated fashion, clustering of patients, and digital pathology. 
However, the field is still poorly understood by most clinicians and pa-
thologists. Several speakers at the 2019 Banff meeting discussed the 
capabilities of AI and the potential for use of ML algorithms in diagnosis 
and personalized medication in organ transplantation (Table 7).
Computer-assisted digital pathology consists of analyzing whole 
slide digital images of biopsies by a machine, and remains a challenge 
aIndividual Banff lesion scores are defined in Table 5, and it is 
recommended that these be included in the biopsy report. 
bIt should be noted that these arterial lesions may be indicative of 
ABMR, TCMR, or mixed ABMR/TCMR. “v” lesions and chronic allograft 
arteriopathy are only scored in arteries having a continuous media with 
≥2 smooth muscle layers. 
cThe clinical significance of these findings may be quite different in 
grafts exposed to anti–blood group antibodies (ABO-incompatible 
allografts), where they do not appear to be injurious to the graft and 
may represent accommodation. However, with anti-HLA antibodies, 
such lesions may progress to chronic ABMR, and more outcome data 
are needed. 
dSeverely atrophic tubules are defined as having each of 3 features: 
diameter <25% of unaffected or minimally affected tubules in the same 
biopsy, an undifferentiated-appearing, cuboidal or flattened epithelium, 
and pronounced wrinkling and/or thickening of the tubular basement 
membrane. 
eIt was felt by the majority of Banff 2019 meeting attendees that 
reporting of chronic active TCMR should be accompanied by a second 
diagnosis of borderline acute TCMR or acute TCMR (with appropriate 
grade) when criteria for both diagnoses are met. 
fpvl scores are defined in Table 5 and in detail in ref. 4. An adequate 
sample for such scoring should include 2 biopsies cores and contain 
medulla. PVN can coexist with ABMR or with TCMR grades 2 or 3. 
TA B L E  4   (Continued)
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even with most advanced image analyzing algorithms such as con-
volutional neural networks. At this point DL-based histopathologic 
assessment of kidney tissue shows the ability to distinguish glom-
eruli, proximal and distal tubules, and areas of fibrosis.28-30 The cur-
rent approach is promising but still shows high variability and poor 
correlation with clinical outcomes. A BWG on Digital Pathology has 
been formed at the 2019 Banff meeting to standardize scanning and 
analytical practices through facilitating studies focusing on IFTA and
inflammation scoring while using algorithms fitting the most cur-
rent Banff classification to decrease inter-observer variability. Because 
personalized medicine has been a major focus in recent years, utiliz-
ing algorithms and archetype analysis has the potential to combine 
biopsy results with clinical and laboratory data and to provide a more 
complete pathologic and prognostic picture, especially in the era of 
expanding electronic medical records.31 Furthermore, A. Loupy pre-
sented the capability of natural language processing (NLP) to help such 
algorithms assist clinicians and reduce human errors. NLP could be used 
for an otherwise time-consuming meta-analysis or accelerated reading 
of large numbers of pathology reports. Finally, since the Banff rules 
are becoming increasing complex with numerous possible scenarios, 
TA B L E  5   Banff reporting standardization scheme: Individual Banff scores used in grading of acute and chronic active ABMR and TCMR. 
Inclusion in the biopsy report of table similar to the below or a simple listing of individual scores in a comment is advised
Acute Banff scores Grading (0, 1, 2, 3) Chronic Banff scores Grading (0, 1, 2, 3)
Acute & chronic Banff 







Abbreviations: i, inflammation in non-scarred cortex, scored as 0 (absent/minimal, <10% of non-scarred cortex inflamed), 1 (mild, 10%-25%), 2 
(moderate 26%-50%), 3 (severe, >50%). The subcapsular cortex should not be considered; t, tubulitis in cortical tubules within non-scarred cortex, 
scored as 0 (none), 1 (mild, 1-4 mononuclear leukocytes per tubular cross-section or 10 tubular epithelial cells in most severely involved tubule), 2 
(moderate, 5-10 mononuclear leukocytes), 3 (severe, >10 mononuclear leukocytes). Although the tubulitis score (1-3) is based on the single most 
severely involved tubule, at least mild tubulitis must be present in ≥2 cortical foci for a t score >0 to be assigned. Severely atrophic tubules should 
NOT be scored; v, endarteritis (intimal arteritis), scored as 0 (none), 1 (mild, 1 or more leukocytes directly beneath the endothelium of 1 or more 
arteries; endothelial cells typically appear enlarged with associated subendothelial edema; <25% luminal occlusion), 2 (moderate, as grade 1, but with 
≥25% luminal occlusion), 3 (severe, with arterial fibrinoid necrosis or transmural inflammation). Note that only arteries (minimum 2 smooth muscle 
layers) are scored; g, glomerulitis, scored as 0 (none), 1 (mild, with ≥1 leukocyte AND associated endothelial swelling occluding >50% of 1 of more 
capillary lumina in at least one but <25% of glomeruli), 2 (moderate, these changes involving 25%-75% of glomeruli), 3 (severe, involving >75% of 
glomeruli). Ischemic, collapsed glomeruli and glomeruli with >50% sclerosis should not be scored; ptc, peritubular capillaritis, scored as 0 (minimal, 
with <3 leukocytes in the most severely involved cortical PTC and/or leukocytes in <10% of cortical PTCs), 1 (mild, with ≥1 leukocyte in ≥10% of 
cortical PTCs AND 3-4 leukocytes in the most severely involved PTC), 2 (moderate, as grade 1 but with 5-10 leukocytes in most severely involved 
PTC), 3 (severe, as grades 1-2 but with >10 leukocytes in most severely involved cortical PTC). The extent of PTC inflammation should be documented 
as focal (10%-50% of cortical PTCs) or diffuse (>50%). Note that medullary capillaries are NOT scored; C4d, linear staining in PTCs or medullary vasa 
recta by immunofluorescence (IF) on frozen sections of fresh tissue or immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue, 
scored as 0 (none), 1 (minimal, staining in >0 but <10% of PTCs), 2 (focal, 10%-50% of PTCs), 3 (diffuse, >50% of PTCs). By IF on frozen sections scores 
≥2 are considered positive; by IHC on paraffin sections all scores >0 are considered positive; ci, interstitial fibrosis in cortex, scored as 0 (minimal, 
≤5%), 1 (mild 6%-25%), 2 (moderate, 26%-50%), 3 (severe, >50%). The subcapsular cortex should not be scored; ct, tubular atrophy in cortex, scored 
as 0 (none), 1 (mild, 1%-25%), 2 (moderate, 26%-50%), 3 (severe, >50%). The subcapsular cortex should not be scored; cv, arterial intimal fibrosis 
(fibrointimal thickening), scored as 0 (none), 1 (mild, present but with ≤25% narrowing of luminal area in the most involved artery), 2 (moderate, 
26%-50% luminal narrowing), 3 (severe, >50% luminal narrowing); cg, chronic glomerulopathy (transplant glomerulopathy), scored as 0 (none, no 
GBM double contours by light microscopy [LM] or EM), 1a (early mild, no GBM double contours by LM but subendothelial neo-densa in ≥3 glomerular 
capillaries by EM with associated endothelial cell enlargement and/or subendothelial electron-lucent widening, 1b (mild, GBM double contours by LM 
in 1%-25% of glomerular capillaries by LM in the most severely involved glomerulus), 2 (moderate, double contours by LM in 26%-50% of capillaries), 
3 (severe, double contours by LM in >50% of capillaries). Ischemic, collapsed glomeruli and glomeruli with >50% sclerosis should not be scored; ptcml, 
peritubular capillary basement membrane multilayering (requires EM), scored as 1 (≥7 basement membrane layers in the most affected PTC AND 
≥5 layers in two additional PTCs), 0 (not meeting these criteria), or NA if EM is not performed; ti, total cortical inflammation, including scarred and 
non-scarred cortex, scored as 0 (absent/minimal, <10%), 1 (mild, 10%-25%), 2 (moderate, 26%-50%), 3 (severe, >50%); i-IFTA, inflammation in scarred 
cortex, scored as 0 (absent/minimal, <10% of non-scarred cortex inflamed OR if the extent of cortical IFTA is <10%), 1 (mild, 10%-25% of scarred 
cortex inflamed), 2 (moderate 26%-50% of scarred cortex inflamed), 3 (severe, >50% of scarred cortex inflamed). The subcapsular cortex should not 
be considered; t-IFTA, tubulitis in tubules within scarred cortex, scored as 0 (none), 1 (mild, 1-4 mononuclear leukocytes per tubular cross-section 
or 10 tubular epithelial cells in most severely involved tubule), 2 (moderate, 5-10 mononuclear leukocytes), 3 (severe, >10 mononuclear leukocytes). 
Severely atrophic tubules should NOT be scored; pvl, intrarenal polyomavirus load level, defined by the overall fraction of tubules in the entire biopsy 
(cortex and medulla) with at least 1 epithelial cell showing a viral inclusion body by light microscopy OR nuclear staining for SV40 large T antigen by 
IHC. As IHC is more sensitive, proper pvl scoring requires IHC. Scored as 0 (none), 1 (mild, positive cells in ≤1% of tubules), 2 (moderate, >1% and 
<10%), 3 (severe, ≥10%). The pvl score in combination with the ci score is used to define the PVN class (Table 4).
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there is increasing demand for an automated coding of Banff rules. 
This would require integration of experienced pathologists to decode 
the Banff rules and computer/data scientists to create an algorithm to 
apply the Banff rules. Key to achieving quality results from ML-based 
diagnosis are the integration of multiple centers providing quality input 
data to construct a standardized and reproducible analytical process.
5  | CONCLUSIONS
The international consensus-building framework provided by the 
Banff process is ongoing. Much has been done in the field of diag-
nostic assessment of allograft pathology, but many issues remain to 
be studied further. Although our experience in continually updating 
F I G U R E  1   Responses to TTS survey regarding the management of chronic active (CA) TCMR: of the 128 respondents to this survey, 47 
(37%) were from Europe, 26 (20%) from Asia, 23 (18%) from the United States and Canada, 18 (14%) from Latin America, 9 (7%) from the 
Middle East and Africa, and 5 (4%) from Australia and New Zealand. Sixty-five percent of centers performed <100 renal transplantations 



























Routinely Under condition Rarely
- No severe IFTA (47%) 
- Depending on i and v (49%)
- If for cause biopsy (4%) 
36% 15% 49 % 
- Lack of data (64%)
- Risks outweighs benefits or 
experience of ineffectiveness (27%)
- Pathologists do not diagnose CA 
TCMR (9%) 
%
How do you treat ? Which response rate do you observe?
When do you treat CA TCMR ?
TA B L E  7   Feasible applications of artificial intelligence in the Banff classification
Type Fields of usage Popular algorithms
Image recognition Digital pathology CNN, ResNet, VGG, etc
NLP Meta-analysis SyntaxNet, transfer learning, SVM, naive 
Bayes classifier, etc
Text mining Meta-analysis, automated report, report/web 
scraping
k-means clustering, naive Bayes classifier, 
KNN, SVM, etc
Cluster pattern recognition Gene expression, personalized medicine Linkage algorithms, k-means, DBSCAN, 
archetypal analysis, etc
Class prediction Graft lost, response to therapy Random forest, multinomial logistic 
regression, SVM, neural network, etc
Abbreviations: CNN, convolutional neural network; DBscan, description density-based spatial clustering of applications with noise; KNN, K nearest 
neighbors; NLP, natural language processing; SVM, support vector machine; VGG, visual geometry group.
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the diagnostic criteria for renal allograft rejection and related le-
sions has improved diagnostic accuracy and clinicopathologic cor-
relations,16 this experience has also helped clarify the limits of 
histology and immunohistology in renal allograft biopsy interpre-
tation and emphasized the need for development of additional 
diagnostic modalities, including molecular diagnostics. Current rec-
ommendations regarding the further clinical validation and use of 
the latter are detailed in a separate meeting report; this and other 
themes will also be addressed at the XVI. Banff meeting, which 
will be held jointly with the Canadian Society of Transplantation 
in Banff, Canada, October 4-7 2021, celebrating the 30-year an-
niversary of the Banff classification at the original location of its 
inception.
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